Age: 68.0
Sex: F
Vaccine: COVID19
Symptoms: Alopecia, Eye disorder, Pain, Skin mass
Clinical narrative: bumps on her scalp, nose, around her ears, in her ears, and her face; lost all my hair/almost bald/bald spots all over my head now; bumps hurt; Eyes became matted; This spontaneous case was reported by a consumer and describes the occurrence of SKIN MASS (bumps on her scalp, nose, around her ears, in her ears, and her face) in a 69-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 028L20A and 013L20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Concurrent medical conditions included Diabetes since 30-Jun-1997 and Hypertension since 1980. Concomitant products included HYDROCHLOROTHIAZIDE, VALSARTAN (VALSARTAN & HCTZ) from 11-Jan-2018 to an unknown date for Blood pressure, METFORMIN HYDROCHLORIDE, SITAGLIPTIN PHOSPHATE MONOHYDRATE (JANUMET) from 11-Jan-2018 to an unknown date, DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE (FARXIGA) from 08-Jan-2021 to an unknown date and GLIPIZIDE from 11-Jan-2018 to an unknown date for Diabetes, VITAMIN D2 from 11-Jan-2018 to an unknown date for an unknown indication.   On 26-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 23-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. In May 2021, the patient experienced EYE DISORDER (Eyes became matted). On an unknown date, the patient experienced SKIN MASS (bumps on her scalp, nose, around her ears, in her ears, and her face) (seriousness criterion hospitalization), ALOPECIA (lost all my hair/almost bald/bald spots all over my head now) and PAIN (bumps hurt). The patient was hospitalized on 05-Apr-2021 due to SKIN MASS. The patient was treated with BACITRACIN ZINC, NEOMYCIN SULFATE, POLYMYXIN B SULFATE (NEOSPORIN TOPICAL) for Adverse event, at an unspecified dose and frequency and TRIAMCINOLONE ACETONIDE for Adverse event, at an unspecified dose and frequency. At the time of the report, SKIN MASS (bumps on her scalp, nose, around her ears, in her ears, and her face), ALOPECIA (lost all my hair/almost bald/bald spots all over my head now) and PAIN (bumps hurt) had not resolved and EYE DISORDER (Eyes became matted) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   It was reported that the bumps went on one side of patient's head, then went away, then come back on the other side of her head. The patient never had cancer; she never had radiation. The patient used triamcinolone cream for her bumps, but the cream only took away the bumps on her face and in her ears. The patient used Neosporin on her scalp which worked better than the triamcinolone cream . The patient received allergy pills, eye drops and cream. It cleared all areas except her scalp.  Initial in May of 2021, the patient went to the doctor because her eyes became matted.  Company comment: This case concerns a 59-year-old female patient no relevant medical history, who experienced serious, unlisted event of skin mass, among other non-serious events. The events occurred on an unknown day after 2nd dose of Moderna COVID-19 Vaccine. The rechallenge was not applicable as the event occurred after 2nd dose of Moderna COVID-19 Vaccine. The benefit-risk relationship of Moderna COVID-19 Vaccine is not affected by this report.   Most recent FOLLOW-UP information incorporated above includes: On 21-Sep-2021: Follow-up received provided reporter's additional contact information, patient initials, patient demographics, medical history, concomitant medications, treatment medication, event and event seriousness.; Sender's Comments: This case concerns a 59-year-old female patient no relevant medical history, who experienced serious, unlisted event of skin mass, among other non-serious events. The events occurred on an unknown day after 2nd dose of Moderna COVID-19 Vaccine. The rechallenge was not applicable as the event occurred after 2nd dose of Moderna COVID-19 Vaccine. The benefit-risk relationship of Moderna COVID-19 Vaccine is not affected by this report.